Logo

CYSTIC FIBROSIS (MUCOVISCIDOSIS): PATHOGENESIS, CLINICAL MANIFESTATIONS, AND MODERN APPROACHES TO DIAGNOSIS AND MANAGEMENT

Authors

  • Erkinov Jamshidbek Khusanboy ugli

    Namangan International Medical College, University of Business and Science, Namangan, Uzbekistan
    Author
  • Turayev Khusniddin Zayniddin ugli

    Namangan International Medical College, University of Business and Science, Namangan, Uzbekistan
    Author

Keywords:

cystic fibrosis, mucoviscidosis, CFTR, genetic disease, pulmonary complications, pancreatic insufficiency

Abstract

Cystic fibrosis (CF), also known as mucoviscidosis, is one of the most common life-threatening autosomal recessive genetic disorders affecting multiple organ systems. The disease results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to abnormal chloride ion transport and production of thick secretions in the respiratory, gastrointestinal, and reproductive systems. This study aimed to analyze current knowledge regarding the pathogenesis, clinical manifestations, diagnosis, and management of cystic fibrosis. A comprehensive review of contemporary scientific literature was performed. The findings indicate that early diagnosis and multidisciplinary management significantly improve patient outcomes and quality of life. Recent advances in CFTR modulator therapies have transformed the treatment landscape and increased life expectancy among affected individuals. Continued research is essential for optimizing personalized treatment strategies and improving long-term prognosis.

References

1. Elborn J.S. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531.

2. Ratjen F., Bell S.C., Rowe S.M., Goss C.H., Quittner A.L., Bush A. Cystic fibrosis. Nature Reviews Disease Primers. 2015;1:15010.

3. Cutting G.R. Cystic fibrosis genetics: from molecular understanding to clinical application. Nature Reviews Genetics. 2015;16(1):45–56.

4. Middleton P.G., Mall M.A., Dřevínek P., et al. Elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis. New England Journal of Medicine. 2019;381(19):1809–1819.

5. Bell S.C., Mall M.A., Gutierrez H., et al. The future of cystic fibrosis care. Lancet Respiratory Medicine. 2020;8(1):65–124.

6. Davis P.B. Cystic fibrosis since 1938. American Journal of Respiratory and Critical Care Medicine. 2006;173(5):475–482.

7. Rosenstein B.J., Cutting G.R. The diagnosis of cystic fibrosis. New England Journal of Medicine. 1998;338(20):1531–1534.

8. Rowe S.M., Miller S., Sorscher E.J. Cystic fibrosis. New England Journal of Medicine. 2005;352(19):1992–2001.

Downloads

Published

2026-06-09